Intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) has been shown to be an effective treatment to slow the progression of neovascular age-related macular degeneration (nAMD) and sustain visual acuity (VA) [4, 5]. The gene discussed is VEGFA; the disease is wet macular degeneration.